U.S. FDA approves first generic drug for asthma and COPD treatment
Category: #health  By Mateen Dalal  Date: 2019-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves first generic drug for asthma and COPD treatment

The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases.

The U.S. Food and Drug Administration recently announced that it has approved the first generic version of Advair Diskus for asthma treatment in patients aged four years and above. Approval has been granted for 500 mcg/50 mcg, 250 mcg/50 mcg and 100 mcg/50 mcg doses of the generic drug, which is indicated for twice daily treatment of patients suffering from chronic obstructive pulmonary disease which include emphysema and bronchitis besides being approved for asthma.

The newly approved generic drug is reported to contain long-acting beta(2)-adrenergic agonist (LABA) and corticosteroid which help in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and treatment of airflow obstruction. For the record, this is a complex drug-device combination medical product and no generic medical product of the same kind has won an FDA approval before this.

Janet Woodcock, MD and director of Center for Drug Evaluation and Research, FDA, has been reported by a press release to say that the approval of the generic drug product for the most frequently prescribed asthma and COPD inhalers in the country, demonstrates FDA’s commitment towards advancing access to high quality yet low-cost generic alternatives. She added that people with COPD and asthma understand and experience the critical importance of being able to afford the treatment to feel healthy and the recent approval is yet another step towards benefitting those who rely on this drug besides increasing market competition.

For the record, 26 million people in the U.S., which includes children as well, suffer from asthma while an additional 16 million people have to fight COPD. Availability of generic medicines for these disorders are a basic benefit that the citizens will be able to access through the recent approval.

According to sources, the FDA approves of generic drugs once it is satisfied that the generic drug is as effective and as safe as the brand name drug. For this approval the generic drug has to undergo rigorous approval standards. The generic drug also has to maintain the same packaging and manufacturing standards as the branded drug.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...